share_log

ZyVersa Therapeutics | DEFA14A: Others

ZyVersa Therapeutics | DEFA14A: Others

ZyVersa Therapeutics | DEFA14A:其他
SEC announcement ·  03/27 17:05
Moomoo AI 已提取核心訊息
ZyVersa Therapeutics, Inc. has announced that starting March 27, 2024, Morrow Sodali LLC, the company's proxy solicitors, will disseminate an audio recording from the Chief Financial Officer, Peter Wolfe, to certain stockholders. The communication is part of the preparations for the upcoming 2024 Special Meeting of Stockholders scheduled for April 17, 2024. In the recording, Wolfe discusses the current biotech environment, characterized by low valuations and reduced capital availability, and outlines the company's strategy to navigate these challenges. One of the strategies mentioned is a potential reverse stock split to maintain compliance with Nasdaq's listing requirements and to make the stock more attractive to new investors. However, Wolfe expresses hope that this measure will not be necessary, citing increased investor confidence due...Show More
ZyVersa Therapeutics, Inc. has announced that starting March 27, 2024, Morrow Sodali LLC, the company's proxy solicitors, will disseminate an audio recording from the Chief Financial Officer, Peter Wolfe, to certain stockholders. The communication is part of the preparations for the upcoming 2024 Special Meeting of Stockholders scheduled for April 17, 2024. In the recording, Wolfe discusses the current biotech environment, characterized by low valuations and reduced capital availability, and outlines the company's strategy to navigate these challenges. One of the strategies mentioned is a potential reverse stock split to maintain compliance with Nasdaq's listing requirements and to make the stock more attractive to new investors. However, Wolfe expresses hope that this measure will not be necessary, citing increased investor confidence due to anticipated milestones for the company's lead drugs targeting kidney and inflammatory diseases. Shareholders are urged to vote in favor of the reverse stock split proposal during the virtual Special Meeting, with proxy materials and voting instructions to be mailed to them. The company emphasizes the importance of shareholder votes and appreciates their ongoing support.
ZyVersa Therapeutics, Inc.宣佈,從2024年3月27日起,該公司的代理律師Morrow Sodali LLC將向某些股東傳播首席財務官彼得·沃爾夫的錄音。該通報是定於2024年4月17日舉行的2024年股東特別會議籌備工作的一部分。在錄音中,沃爾夫討論了當前以低估值和資本可用性減少爲特徵的生物技術環境,並概述了公司應對這些挑戰的戰略。提到的策略之一是可能進行反向股票拆分,以保持對納斯達克上市要求的合規性,並使股票對新投資者更具吸引力。但是,沃爾夫表示希望沒有必要採取這項措施,理由是該公司針對腎臟和炎症性疾病的主要藥物預計將出現里程碑,投資者信心增強。敦促股東在虛擬特別會議期間對反向股票拆分提案投贊成票,並將代理材料和投票說明郵寄給他們。該公司強調股東投票的重要性,並感謝他們的持續支持。
ZyVersa Therapeutics, Inc.宣佈,從2024年3月27日起,該公司的代理律師Morrow Sodali LLC將向某些股東傳播首席財務官彼得·沃爾夫的錄音。該通報是定於2024年4月17日舉行的2024年股東特別會議籌備工作的一部分。在錄音中,沃爾夫討論了當前以低估值和資本可用性減少爲特徵的生物技術環境,並概述了公司應對這些挑戰的戰略。提到的策略之一是可能進行反向股票拆分,以保持對納斯達克上市要求的合規性,並使股票對新投資者更具吸引力。但是,沃爾夫表示希望沒有必要採取這項措施,理由是該公司針對腎臟和炎症性疾病的主要藥物預計將出現里程碑,投資者信心增強。敦促股東在虛擬特別會議期間對反向股票拆分提案投贊成票,並將代理材料和投票說明郵寄給他們。該公司強調股東投票的重要性,並感謝他們的持續支持。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息